Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$61.17 USD
-0.15 (-0.24%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $61.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
Ionis Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
IONS 61.17 -0.15(-0.24%)
Will IONS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Other News for IONS
Is IONS ready to make a move? NR7 shows up after gaining 0.36%
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Eli Lilly & Co (LLY) and Revvity (RVTY)
Technical picture remains unchanged for IONS after it falls 3.23% on September 15
Insider Sell: Patrick O'Neil Sells 1,700 Shares of Ionis Pharmaceuticals Inc (IONS)
IONS falls 1.33% on September 12, leaving the technical picture intact